ES2188426A1 - Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. - Google Patents
Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.Info
- Publication number
- ES2188426A1 ES2188426A1 ES200102836A ES200102836A ES2188426A1 ES 2188426 A1 ES2188426 A1 ES 2188426A1 ES 200102836 A ES200102836 A ES 200102836A ES 200102836 A ES200102836 A ES 200102836A ES 2188426 A1 ES2188426 A1 ES 2188426A1
- Authority
- ES
- Spain
- Prior art keywords
- psoriasis
- treatment
- denotes
- pharmaceutical composition
- skin diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000004681 Psoriasis Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 title abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 2
- 229960004703 clobetasol propionate Drugs 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 abstract 2
- 239000006210 lotion Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 230000009291 secondary effect Effects 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composición farmacéutica para el tratamiento de la psoriasis y otras dermopatías. Comprende 17-propionato de clobetasol, 11alfa- hidroxiprogesterona (o alternativamente 11 alfa- acetoxiprogesterona) y cantidades adecuadas de excipientes para constituir una formulación tópica. Preferiblemente se administra como loción con: 0,05-0,2% de 17-propionato de clobetasol; 0,3-1% de 11alfa-hidroxiprogesterona; un disolvente seleccionado entre etanol, isopropanol y sus mezclas; un 40% de codisolvente seleccionado entre propilenglicol, glicerina, sorbitol y sus mezclas; y un 20% de agua. Es especialmente preferida la loción donde el disolvente es etanol, y los codisolventes son aproximadamente: 35% de propilenglicol, 5% de glicerina y 20% de agua. Respecto a los tratamientos conocidos con corticoides tópicos, la composición de la invención presenta las ventajas de una recidiva mucho más espaciada y de muchos menos efectos secundarios locales. La composición es útil para el tratamiento de la psoriasis.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200102836A ES2188426B1 (es) | 2001-12-12 | 2001-12-12 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
CA002470364A CA2470364A1 (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
PT02796785T PT1473300E (pt) | 2001-12-12 | 2002-12-11 | Composição farmacêutica para o tratamento de psoríase e outras doenças de pele |
EP02796785A EP1473300B1 (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
AU2002361265A AU2002361265A1 (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
JP2003554707A JP2005513139A (ja) | 2001-12-12 | 2002-12-11 | 乾癬及び他の皮膚疾患の治療のための製薬組成物 |
AT02796785T ATE415410T1 (de) | 2001-12-12 | 2002-12-11 | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten |
ES02796785T ES2318061T3 (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
DE60230066T DE60230066D1 (de) | 2001-12-12 | 2002-12-11 | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten |
PCT/ES2002/000591 WO2003053991A1 (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias |
US10/865,991 US20040225140A1 (en) | 2001-12-12 | 2004-06-11 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200102836A ES2188426B1 (es) | 2001-12-12 | 2001-12-12 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2188426A1 true ES2188426A1 (es) | 2003-06-16 |
ES2188426B1 ES2188426B1 (es) | 2004-11-16 |
Family
ID=8499799
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200102836A Expired - Lifetime ES2188426B1 (es) | 2001-12-12 | 2001-12-12 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
ES02796785T Expired - Lifetime ES2318061T3 (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02796785T Expired - Lifetime ES2318061T3 (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20040225140A1 (es) |
EP (1) | EP1473300B1 (es) |
JP (1) | JP2005513139A (es) |
AT (1) | ATE415410T1 (es) |
AU (1) | AU2002361265A1 (es) |
CA (1) | CA2470364A1 (es) |
DE (1) | DE60230066D1 (es) |
ES (2) | ES2188426B1 (es) |
PT (1) | PT1473300E (es) |
WO (1) | WO2003053991A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2070533A1 (en) | 2007-12-11 | 2009-06-17 | Apoteknos Para La Piel, s.l. | Use of a compound derived from P-hydroxyphenyl propionic acid for the treatment of psoriasis |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2898499B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
FR2898498B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
ES2288133B1 (es) | 2006-06-12 | 2008-09-16 | Maria Cristina Fernandez Rodriguez | Composicion topica para el tratamiento de la psoriasis. |
PT1891960E (pt) * | 2006-08-17 | 2010-01-04 | Klever Mode S L | Fórmula farmacêutica para o tratamento de doenças da pele |
EP2701744A4 (en) * | 2011-03-23 | 2014-08-20 | Pop Test Cortisol Llc | COMBINATION THERAPY |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2015179782A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP3174542A4 (en) | 2014-07-29 | 2018-01-03 | TherapeuticsMD, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017037663A1 (en) | 2015-09-02 | 2017-03-09 | Cadila Healthcare Limited | Topical compositions comprising corticosteroids |
RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998036753A1 (en) * | 1997-02-20 | 1998-08-27 | Allergan Sales,Inc. | Tazarotene and corticosteroid treatment for psoriasis |
US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966924A (en) * | 1974-11-13 | 1976-06-29 | Allergan Pharmaceuticals | Composition and method for treating psoriasis |
JPS56135416A (en) * | 1980-03-27 | 1981-10-22 | Mitsubishi Chem Ind Ltd | Pharmaceutical preparation for skin |
AU667519B2 (en) * | 1992-02-07 | 1996-03-28 | Albert M. Kligman | Methods of treating inflammatory dermatoses |
WO1994013257A1 (en) * | 1992-12-16 | 1994-06-23 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
-
2001
- 2001-12-12 ES ES200102836A patent/ES2188426B1/es not_active Expired - Lifetime
-
2002
- 2002-12-11 CA CA002470364A patent/CA2470364A1/en not_active Abandoned
- 2002-12-11 EP EP02796785A patent/EP1473300B1/en not_active Expired - Lifetime
- 2002-12-11 AT AT02796785T patent/ATE415410T1/de active
- 2002-12-11 ES ES02796785T patent/ES2318061T3/es not_active Expired - Lifetime
- 2002-12-11 WO PCT/ES2002/000591 patent/WO2003053991A1/es active Application Filing
- 2002-12-11 PT PT02796785T patent/PT1473300E/pt unknown
- 2002-12-11 AU AU2002361265A patent/AU2002361265A1/en not_active Abandoned
- 2002-12-11 DE DE60230066T patent/DE60230066D1/de not_active Expired - Lifetime
- 2002-12-11 JP JP2003554707A patent/JP2005513139A/ja active Pending
-
2004
- 2004-06-11 US US10/865,991 patent/US20040225140A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998036753A1 (en) * | 1997-02-20 | 1998-08-27 | Allergan Sales,Inc. | Tazarotene and corticosteroid treatment for psoriasis |
US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
Non-Patent Citations (2)
Title |
---|
BARAN, R. et al.: "Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation". J. of Dermatological Treatment, 1999, Volumen 10, pßginas 201-204, todo el documento. * |
SWINKELS, O.Q.J. et al.: "The influence of a topical corticosteroid on short-contact high-dose dithranol therapy". British J. of Dermatology, 2001, Volumen 145, pßginas 63-69, todo el documento. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2070533A1 (en) | 2007-12-11 | 2009-06-17 | Apoteknos Para La Piel, s.l. | Use of a compound derived from P-hydroxyphenyl propionic acid for the treatment of psoriasis |
Also Published As
Publication number | Publication date |
---|---|
CA2470364A1 (en) | 2003-07-03 |
ES2318061T3 (es) | 2009-05-01 |
PT1473300E (pt) | 2009-02-27 |
US20040225140A1 (en) | 2004-11-11 |
ATE415410T1 (de) | 2008-12-15 |
EP1473300B1 (en) | 2008-11-26 |
WO2003053991A1 (es) | 2003-07-03 |
DE60230066D1 (de) | 2009-01-08 |
EP1473300A1 (en) | 2004-11-03 |
ES2188426B1 (es) | 2004-11-16 |
JP2005513139A (ja) | 2005-05-12 |
AU2002361265A1 (en) | 2003-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2188426A1 (es) | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. | |
MY119181A (en) | Aryl pyrimidine derivatives | |
ATE252529T1 (de) | Colchinolderivate als gefässschädigende mittel | |
WO2002022598A8 (en) | Quinolinone derivatives as tyrosine kinase inhibitors | |
MXPA03005464A (es) | Agentes antivirales. | |
WO2003053368A3 (en) | Chalcone derivatives and their use to treat diseases | |
BR9909796B1 (pt) | "derivados de piperidinopirimidina para aplicação tópica" | |
WO2005011653A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
DK1392329T3 (da) | Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom | |
CA2419404A1 (en) | Compositions and methods for treating sexual dysfunction | |
JP2008539236A5 (es) | ||
TR199802060T2 (xx) | Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�. | |
JPH0662390B2 (ja) | ラクタムを含有する化粧品組成物 | |
BR0109515A (pt) | Derivados da apomorfina e métodos para seu uso | |
JPH0517365A (ja) | テストステロン 5α−レダクターゼ阻害剤 | |
WO2002047673A3 (en) | Methods and compositions to treat conditions associated with neovascularization | |
WO2002042319A3 (en) | 2-substituted estrogens as antiangiogenic agents | |
DE60031686D1 (de) | Pyrazinone, diese verbindungen enthaltende zusammenstellungen | |
JPH06502161A (ja) | レチノイド浸透作用エンハンサーを含む局所用組成物 | |
MX2007013466A (es) | Composicion cosmetica. | |
TW200501995A (en) | Treatment for skin | |
DK1194109T3 (da) | Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf | |
AP9801235A0 (en) | Erythromycin derivatives. | |
EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
NO20032407D0 (no) | Anvendelse av 6-dimetylaminometyl-1-fenyl- cykloheksanforbindelser for behandling av urininkontinens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20030616 Kind code of ref document: A1 |
|
FG2A | Definitive protection |
Ref document number: 2188426B1 Country of ref document: ES |
|
FA2A | Application withdrawn |
Effective date: 20050401 |